61
Participants
Start Date
December 23, 2019
Primary Completion Date
May 15, 2026
Study Completion Date
May 15, 2026
Cusatuzumab
Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
Azacitidine
Azacitidine will be administered 75 mg/m\^2 subcutaneously or intravenously.
Venetoclax
Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
INSELSPITAL, Universitätsspital Bern, Bern
Kantonsspital St.Gallen, Sankt Gallen
Weill Cornell Medicine, New York
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
University of Rochester, Rochester
University of Pittsburgh School of Medicine, Pittsburgh
Universitaetsklinik Hamburg-Eppendorf, Hamburg
Norton Cancer Institute, Louisville
Barbara Ann Karmanos Cancer Institute, Detroit
Wisconsin Medical Center, Milwaukee
The University of Texas MD Anderson Cancer Center, Houston
Klinikum der Universitaet Muenchen, München
City of Hope, Duarte
University of Vermont, Burlington
Tom Baker Cancer Centre, Calgary
University of Alberta Hospital, Edmonton
University of Toronto, Toronto
McGill University Health Centre, Montreal
Universitaetsklinikum Leipzig, Leipzig
Szpital Uniwersytecki w Krakowie, Krakow
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz
Instytut Hematologii i Transfuzjologii, Warsaw
Lead Sponsor
Collaborators (1)
argenx
INDUSTRY
Janssen Research & Development, LLC
INDUSTRY
OncoVerity, Inc.
INDUSTRY